An announcement from Psyence Biomedical ( (PBM) ) is now available.
Psyence Biomedical Ltd. is advancing its position in the psychedelic medicine industry with a multi-asset strategy, focusing on clinical trials and scalable manufacturing. The company is conducting a Phase IIb clinical trial in Australia for adjustment disorder in cancer patients, leveraging the country’s favorable regulatory environment and tax incentives. This trial, along with strategic partnerships and a strong scientific advisory board, positions Psyence BioMed at the forefront of psychedelic therapeutics. The company is also preparing to launch a clinical trial for Alcohol Use Disorder, addressing significant unmet medical needs. With a strong financial position and strategic growth plans, Psyence BioMed aims to capitalize on the projected growth of the psychedelic mushroom market, enhancing shareholder value and advancing mental health care through psychedelic-assisted therapies.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. It is notable for being the first life sciences biotechnology company focused on developing nature-derived psilocybin-based psychedelic medicine to be listed on Nasdaq.
YTD Price Performance: -71.15%
Average Trading Volume: 380,014
Technical Sentiment Signal: Buy
Current Market Cap: $2.34M
For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.